Abstract
Vagus nerve stimulation (VNS) has been widely used to treat different neurological disorders, especially epilepsy. Accumulating evidence also suggests its potential application in antidepressive therapy, given that VNS has been confirmed by several clinical trials to exert long-term effects on mitigating depression and reducing the risk of relapse in depressed patients. Likewise, VNS has also proven to ameliorate the behavioral deficits in a rat model of depression. While the influences of VNS on monoamine metabolism and mood improvement are well-recognized, the underlying mechanisms mediating its antidepressive action remain poorly understood. Recent findings suggest that VNS-enhanced proliferation of hippocampal neural progenitor cells (NPCs) and synaptic transmission might serve as a monoamine-independent pathway contributive to the beneficial effects of VNS on depression. Here we briefly reviewed the recent progress in this field, based on which we propose that there might be, at least, two little-overlapped, and yet interactive pathways mediating the antidepressive action of VNS.
Keywords: Vagus nerve stimulation, depression, neurogenesis, hippocampus, monoamine, brain-derived neurotrophic factor.
Current Molecular Medicine
Title:Vagus nerve stimulation in treating depression: A tale of two stories.
Volume: 16 Issue: 1
Author(s): T.-F. Yuan, A. Li, X. Sun, O. Arias-Carrión and S. Machado
Affiliation:
- Institute de Psychiatry, Federal University of Rio de Janeiro, Brazil.,Brazil
Keywords: Vagus nerve stimulation, depression, neurogenesis, hippocampus, monoamine, brain-derived neurotrophic factor.
Abstract: Vagus nerve stimulation (VNS) has been widely used to treat different neurological disorders, especially epilepsy. Accumulating evidence also suggests its potential application in antidepressive therapy, given that VNS has been confirmed by several clinical trials to exert long-term effects on mitigating depression and reducing the risk of relapse in depressed patients. Likewise, VNS has also proven to ameliorate the behavioral deficits in a rat model of depression. While the influences of VNS on monoamine metabolism and mood improvement are well-recognized, the underlying mechanisms mediating its antidepressive action remain poorly understood. Recent findings suggest that VNS-enhanced proliferation of hippocampal neural progenitor cells (NPCs) and synaptic transmission might serve as a monoamine-independent pathway contributive to the beneficial effects of VNS on depression. Here we briefly reviewed the recent progress in this field, based on which we propose that there might be, at least, two little-overlapped, and yet interactive pathways mediating the antidepressive action of VNS.
Export Options
About this article
Cite this article as:
Yuan T.-F., Li A., Sun X., Arias-Carrión O. and Machado S., Vagus nerve stimulation in treating depression: A tale of two stories., Current Molecular Medicine 2016; 16(1) . https://dx.doi.org/10.2174/1566524016666151222143609
| DOI https://dx.doi.org/10.2174/1566524016666151222143609 |
Print ISSN 1566-5240 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Therapeutic Potentials of Adenosine Receptors: The State of The Art
Current Pharmaceutical Design Genetic Studies on the Role of T-Type Ca2+ Channels in Sleep and Absence Epilepsy
CNS & Neurological Disorders - Drug Targets Pharmacotherapy of Borderline Personality Disorder: A Systematic Review
Current Medicinal Chemistry Recent Advancement in Computer-Aided Drug Design
Current Pharmaceutical Design Neuronal Ceroid Lipofuscinosis: The Increasing Spectrum of an Old Disease
Current Molecular Medicine Obituary
Mini-Reviews in Medicinal Chemistry Intraoperative Seizures: Anesthetic and Antiepileptic Drugs
Current Pharmaceutical Design Decreased Expression of Sox-1 in Cerebellum of Rat with Generalized Seizures Induced by Kindling Model
CNS & Neurological Disorders - Drug Targets The Medicinal Chemistry of 5-HT6 Receptor Ligands with a Focus on Arylsulfonyltryptamine Analogs
Current Topics in Medicinal Chemistry Role of Nicotinic and Muscarinic Receptors on Synaptic Plasticity and Neurological Diseases
Current Pharmaceutical Design Synthesis, Experimental and Computational Studies of N-(4-amino-6-oxo- 1,6-dihydropyrimidin-5-yl)benzamide
Letters in Organic Chemistry Personalizing Medicine in Nigeria by Tailoring the Research Process: Points to Consider for Genomic Research
Current Pharmacogenomics and Personalized Medicine Postnatal Neurogenesis and Dopamine Alterations in Early Psychosis
Recent Patents on CNS Drug Discovery (Discontinued) Inhibition of Monoamine Neurotransmitter Transporters and Central Nervous System Stimulation Induced by Synthetic Local Anesthetics and Cocaine: A Comparative Review-Update
Current Medicinal Chemistry - Central Nervous System Agents Insulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer’s Disease
Current Alzheimer Research Measuring Receptor Occupancy with PET
Current Pharmaceutical Design Brain Serotonin, Psychoactive Drugs, and Effects on Reproduction
Central Nervous System Agents in Medicinal Chemistry Valproate and Neuroendocrine Changes in Relation to Women Treated for Epilepsy and Bipolar Disorder: A Review
Current Medicinal Chemistry Editorial Review 2015
Current Radiopharmaceuticals Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design

